Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity

Nature Communications

Volumn 7, Issue , 2016, Pages

  Laurent, Victor ^a,b   Guérard, Adrien ^a,b   Mazerolles, Catherine ^c   Le Gonidec, Sophie ^a,d   Toulet, Aurélie ^a,b   Nieto, Laurence ^a,b   Zaidi, Falek ^c   Majed, Bilal ^e   Garandeau, David ^a,b   Socrier, Youri ^c   Golzio, Muriel ^a,b   Cadoudal, Thomas ^a,d   Chaoui, Karima ^a,b   Dray, Cedric ^a,d   Monsarrat, Bernard ^a,b   Schiltz, Odile ^a,b   Wang, Yuan Yuan ^a,b   Couderc, Bettina ^a,f   Valet, Philippe ^a,d   Malavaud, Bernard ^a,c   Muller, Catherine ^a,b   more..

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^c Institut Universitaire du Cancer de Toulouse   (France)

^d INSERM   (France)

^e Centre hospitalier de Saint Omer   (France)

^f CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR1 MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CHEMOKINE RECEPTOR CCR3 MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR1 MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 3; NEUTRALIZING ANTIBODY; PLERIXAFOR; SC 202525; UCB 35625; UNCLASSIFIED DRUG;

CANCER; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; GENE EXPRESSION; OBESITY; PROTEIN; SECRETION; TUMOR;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MALE; METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; OBESITY; PERIPROSTATIC ADIPOCYTE; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENCE RISK; ADENOCARCINOMA; ADIPOSE TISSUE; ADULT; AGED; ANIMAL; CELL MOTION; CYTOLOGY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADIPOCYTES; ADIPOSE TISSUE; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL7; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CCR3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84954454073     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10230     Document Type: Article

References (69)

1. Magi-Galluzzi, C. et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod. Pathol. 24, 26-38 (2011).
2. Kapoor, J. et al. Extraprostatic extension into periprostatic fat is a more important determinant of prostate cancer recurrence than an invasive phenotype. J. Urol. 190, 2061-2066 (2013).
3. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97 (2011).
4. Wang, Y. Y. et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett. 324, 142-151 (2012).
5. Allott, E. H., Masko, E. M. & Freedland, S. J. Obesity and prostate cancer: weighing the evidence. Eur. Urol. 63, 800-809 (2013).
6. Parker, A. S. et al. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic. Dis. 16, 352-356 (2013).
7. van Roermund, J. G. et al. Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJU Int. 107, 1775-1779 (2011).
8. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer 4, 540-550 (2004).
9. Vindrieux, D., Escobar, P. & Lazennec, G. Emerging roles of chemokines in prostate cancer. Endocr. Relat. Cancer 16, 663-673 (2009).
10. Zhang, S. et al. Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J. Exp. Clin. Cancer Res. 27, 62 (2008).
11. Lu, Y. et al. CCR2 expression correlates with prostate cancer progression. J. Cell Biochem. 101, 676-685 (2007).
12. Murphy, C. et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin. Cancer Res. 11, 4117-4127 (2005).
13. Zhu, F., Liu, P., Li, J. & Zhang, Y. Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol. Rep. 31, 2049-2054 (2014).
14. Lee, Y. J. et al. Chemokine receptor CCR3 expression in malignant cutaneous tumors. Ann. Dermatol. 22, 412-417 (2010).
15. Johrer, K. et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin. Cancer Res. 11, 2459-2465 (2005).
16. Huber, J. et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J. Clin. Endocrinol. Metab. 93, 3215-3221 (2008).
17. Elsner, J., Escher, S. E. & Forssmann, U. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 59, 1243-1258 (2004).
18. Rosenkilde, M. M. et al. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 279, 3033-3041 (2004).
19. White, J. R. et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273, 10095-10098 (1998).
20. Cherney, R. J. et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J. Med. Chem. 51, 721-724 (2008).
21. Sabroe, I. et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275, 25985-25992 (2000).
22. Muller, C., Nieto, L. & Valet, P. in Adipose Tissue and Cancer 121-146 (2013).
23. Proudfoot, A. E. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2, 106-115 (2002).
24. Xu, L. L. et al. Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors: binding and signaling of MCP3 through shared as well as unique receptors on monocytes and neutrophils. Eur. J. Immunol. 25, 2612-2617 (1995).
25. Celis, J. E. et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelialadipocyte stromal cell interactions. Mol. Cell Proteomics 4, 492-522 (2005).
26. Kabir, S. M., Lee, E. S. & Son, D. S. Chemokine network during adipogenesis in 3T3-L1 cells: Differential response between growth and proinflammatory factor in preadipocytes vs. adipocytes. Adipocyte 3, 97-106 (2014).
27. Cheng, J. W. et al. The role of CXCL12 and CCL7 chemokines in immune regulation, embryonic development, and tissue regeneration. Cytokine 69, 277-283 (2014).
28. Hwang, T. L. et al. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J. Gastroenterol. 18, 1249-1256 (2012).
29. Cho, Y. B. et al. CC chemokine ligand 7 expression in liver metastasis of colorectal cancer. Oncol. Rep. 28, 689-694 (2012).
30. Ayala, A. G., Ro, J. Y., Babaian, R., Troncoso, P. & Grignon, D. J. The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am. J. Surg. Pathol. 13, 21-27 (1989).
31. Couillard, C. et al. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int. J. Obes. Relat. Metab. Disord. 24, 782-788 (2000).
32. Kim, D. et al. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia 57, 1456-1465 (2014).
33. Pierorazio, P. M., Walsh, P. C., Partin, A. W. & Epstein, J. I. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 111, 753-760 (2013).
34. Stark, J. R. et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J. Clin. Oncol. 27, 3459-3464 (2009).
35. Sysel, A. M., Valli, V. E., Nagle, R. B. & Bauer, J. A. Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts. Anticancer Res. 33, 4203-4212 (2013).
36. Chatterjee, S. et al. Quantitative immunohistochemical analysis reveals association between sodium iodide symporter and estrogen receptor expression in breast cancer. PLoS ONE 8, e54055 (2013).
37. Kukreja, P., Abdel-Mageed, A. B., Mondal, D., Liu, K. & Agrawal, K. C. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res. 65, 9891-9898 (2005).
38. Malavaud, B. et al. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur. J. Cancer 46, 3417-3424 (2010).
39. Somers, K. D. et al. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int. J. Cancer 107, 773-780 (2003).
40. Lin, S., Thomas, T. C., Storlien, L. H. & Huang, X. F. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. Relat. Metab. Disord. 24, 639-646 (2000).
41. Nieman, K. M., Romero, I. L., Van Houten, B. & Lengyel, E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim. Biophys. Acta 1831, 1533-1541 (2013).
42. Bochet, L. et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73, 5657-5668 (2013).
43. Dirat, B. et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455-2465 (2011).
44. Dirat, B., Bochet, L., Escourrou, G., Valet, P. & Muller, C. Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocr. Dev. 19, 45-52 (2010).
45. Hefetz-Sela, S. & Scherer, P. E. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol. Ther. 138, 197-210 (2013).
46. Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503 (2011).
47. Finley, D. S. et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J. Urol. 182, 1621-1627 (2009).
48. Ribeiro, R. et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J. Exp. Clin. Cancer. Res. 31, 32 (2012).
49. Walter, M., Liang, S., Ghosh, S., Hornsby, P. J. & Li, R. et al. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28, 2745-2755 (2009).
50. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51 (2007).
51. Chambers, A. F. & Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl Cancer Inst. 89, 1260-1270 (1997).
52. Jung, D. W. et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int. J. Cancer 127, 332-344 (2010).
53. Salazar, N., Castellan, M., Shirodkar, S. S. & Lokeshwar, B. L. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit. Rev. Eukaryot. Gene Expr. 23, 77-91 (2013).
54. Asiedu, M. K., Ingle, J. N., Behrens, M. D., Radisky, D. C. & Knutson, K. L. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 71, 4707-4719 (2011).
55. Dairaghi, D. J., Oldham, E. R., Bacon, K. B. & Schall, T. J. Chemokine receptor CCR3 function is highly dependent on local pH and ionic strength. J. Biol. Chem. 272, 28206-28209 (1997).
56. Zadra, G., Photopoulos, C. & Loda, M. The fat side of prostate cancer. Biochim. Biophys. Acta 1831, 1518-1532 (2013).
57. Ewertz, M. et al. Effect of obesity on prognosis after early-stage breast cancer. J. Clin. Oncol. 29, 25-31 (2011).
58. Humphrey, P. A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod. Pathol. 17, 292-306 (2004).
59. Fricker, S. P. et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol. 72, 588-596 (2006).
60. Horoszewicz, J. S. et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37, 115-132 (1980).
61. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H. & Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21, 274-281 (1978).
62. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F. & Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17, 16-23 (1979).
63. Thalmann, G. N. et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer. Res. 54, 2577-2581 (1994).
64. Delenda, C. Lentiviral vectors: optimization of packaging, transduction and gene expression. J. Gene Med. 6(Suppl 1): S125-S138 (2004).
65. Bousquet, E. et al. Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1. Cancer Res. 69, 6092-6099 (2009).
66. Burcelin, R., Crivelli, V., Dacosta, A., Roy-Tirelli, A. & Thorens, B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am. J. Physiol. Endocrinol. Metab. 282, E834-E842 (2002).
67. Gautier, V. et al. Label-free quantification and shotgun analysis of complex proteomes by one-dimensional SDS-PAGE/NanoLC-MS: evaluation for the large scale analysis of inflammatory human endothelial cells. Mol. Cell Proteomics 11, 527-539 (2012).
68. Brizuela, L. et al. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol. Cancer Ther. 11, 1841-1851 (2012).
69. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467-479 (2014).